Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks

Travere Therapeutics announced Thursday that its Phase III study to confirm the effectiveness of its kidney disease drug sparsentan, marketed as Filspari, narrowly missed one of its key endpoints.